Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Mixed evidenceCoverage 5/5 core metricsOperating margin changed -2.4 percentage points from the prior annual period.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Operating margin compressed
Operating margin changed -2.4 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.
- 1 filing risk check flagged
Flagged areas: Dilution.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Revenue expanded
Latest reported annual revenue changed +13.6% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.
- Free cash flow was positive
Latest reported free cash flow was $839,000.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Dilution
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- North America Segment$222M50.2%+12.0% yoy
- Europe The Middle East And Africa Segments$151M34.3%+15.1% yoy
- Asia Pacific Segment$44.3M10.0%+18.9% yoy
- Latin America Segment$24M5.4%+9.6% yoy
Members sum to the consolidated $441M for this period.
- Products$346Mshare n/a+19.2% yoy
- Aortic Stent Grafts$159Mshare n/a+29.5% yoy
- On X$102Mshare n/a+21.1% yoy
- Preservation Services$95.5Mshare n/a-2.9% yoy
- Surgical Sealants$76.6Mshare n/a+3.7% yoy
- Other Products$8.11Mshare n/a-12.5% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Outside the United States$227M51.5%+14.5% yoy
- United States$214M48.5%+12.7% yoy
Members sum to the consolidated $441M for this period.
- North America Segment$58.7M50.5%+22.8% yoy
- Europe The Middle East And Africa Segments$44M37.8%+18.7% yoy
- Asia Pacific Segment$8.69M7.5%+5.8% yoy
- Latin America Segment$4.97M4.3%-16.2% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 3,997 US-listed filers · 317 in Healthcare| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $441M | 42ndof 3,301 middle third | 55thof 291 middle third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | 13.6% | 69thof 3,137 top third | 61stof 277 middle third |
Gross margin gross profit ÷ revenue | 64.4% | 81stof 1,603 top third | 70thof 212 top third |
Operating margin operating income ÷ revenue | 7.7% | 63rdof 2,819 middle third | 70thof 280 top third |
Net margin net income ÷ revenue | 2.2% | 50thof 3,263 middle third | 62ndof 290 middle third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | 0.2% | 35thof 2,679 middle third | 47thof 261 middle third |
Return on equity net income ÷ stockholders' equity (positive equity only) | 2.2% | 46thof 3,576 middle third | 63rdof 291 middle third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 5.5% | 33rdof 2,895 middle third | 38thof 272 middle third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 74 days | 23rdof 2,398 bottom third | 22ndof 266 bottom third |
Net debt ÷ operating cash flow net debt ÷ operating cash flow (OCF > 0) · lower is ranked higher | 3.8× | 36thof 1,546 middle third | 27thof 116 bottom third |
Cash conversion operating cash flow ÷ net income (net income > 0) | 4.1× | 88thof 1,444 top third | 91stof 95 top third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | -3.6% | 43rdof 1,869 middle third | 34thof 139 middle third |
Balance-sheet accrual ratio change in net operating assets ÷ average net operating assets · lower is ranked higher | 10.8% | 39thof 1,551 middle third | 31stof 116 bottom third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2025-12-31 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 4 changed periods| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Debt issued ProceedsFromIssuanceOfLongTermDebt | quarter 2024-03-31 | $30M 10-Q 2024-05-07 | $190M 10-Q 2025-05-06 | +533.3% | first · latest |
| Capital expenditure PaymentsToAcquirePropertyPlantAndEquipment | fiscal year 2023-12-31 | $7.43M 10-K 2024-02-23 | $9.75M 10-K 2026-02-18 | +31.3% | first · latest · 3 filings carry it |
| Capital expenditure PaymentsToAcquirePropertyPlantAndEquipment | quarter 2023-03-31 | $2.24M 10-Q 2023-05-05 | $2.84M 10-Q 2024-05-07 | +27.0% | first · latest |
| Capital expenditure PaymentsToAcquirePropertyPlantAndEquipment | fiscal year 2022-12-31 | $9.02M 10-K 2023-02-23 | $10.7M 10-K 2025-02-28 | +18.8% | first · latest · 3 filings carry it |
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
Not available for AORT yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.